Indivior Investors - INDV

Indivior Investors - INDV

Buy
Sell
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Indivior Plc INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change Price Change % Stock Price Last Trade
-0.10 -0.07% 133.70 12:03:36
Open Price Low Price High Price Close Price Previous Close
131.50 131.50 134.70 133.80
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Top Investor Posts

DateSubject
18/2/2021
16:27
waldron: Proactiveinvestors Philip Whiterow 08:34 Thu 18 Feb 2021 Follow Philip on: Investor deep dive Symphony Environmental makes progress in battle against COVID-19 read more > viewIndivior PLC Indivior in red after legal settlements take toll Losses for the year were US$173mln with a US$14mln deficit in the final three months Indivior PLC - Suboxone's market share is falling rapidly Indivior PLC (LON:INDV) posted an improvement in sales in the final quarter of 2020 as Sublocade, its injectable, extended-release opioid dependency treatment, picked up momentum. The drug group is trying to build sales of Sublocade to offset a steady decline by its predecessor Suboxone, which has now come off patent. Revenues for the year to end-December fell 18% to US$647mln though there was a 39% jump in the final quarter as sales of Sublocade rose 18%. Losses for the year were US$173mln with a US$14mln deficit in the final three months. During the year, Indivior settled outstanding legal cases with the US Department of Justice and former parent Reckitt Benckiser and Indivior took one-off charges of US$244mln in the 2020 numbers. Mark Crossley, chief executive, said that given the problems related to the coronavirus pandemic he was 'delighted' with the numbers. “Critically, we materially de-risked the business with resolution of the DOJ and RB matters and we took decisive strategic alignment actions which place Indivior on a clear path towards realizing the transformational potential of Sublocade. “Accelerating the growth of Sublocade remains the biggest potential driver of value creation.“ Indivior’s base case assumptions for 2021 are for net revenues to rise to US$625mln with Sublocade net revenues of between US185mln and $210mln (2020: US$130mln).
05/2/2021
17:34
la forge: 04 February 2021 Indivior to Announce FY 2020 Results and Host a Presentation on February 18(th) Slough, UK, and Richmond, VA, February 4, 2021 - Indivior PLC (LON: INDV) today announced that it will release its FY 2020 results on February 18th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com . Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 12:00 GMT (7:00 a.m. U.S. Eastern) on February 18th. Access to the Live Webcast Presentation The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. The webcast link is Https://edge.media-server.com/mmc/p/23dggtiy . Participants may access the presentation telephonically : -- US participants 1-646-741-3167 -- International participants +44 (0) 2071-928338 Please reference confirmation ID 3290938. A replay of the presentation will be available at www.indivior.com .
18/1/2021
19:19
timmy11: RE: Interesting analysis of Indivior (Litigation Investor)Today 14:44 This Report is excellent, very comprehensive & well worth the read. Some of the points it makes are as follows: "Suboxone sales have remained resilient in the face of generic competition (and even saw modest growth in the most recent quarter, Q3 2020) Sublocade unit growth is accelerating (growing 15% in Q3 2020 over Q2 2020) Sublocade sales should easily exceed management guidance A competitive entrant, Brixadi, has been delayed (likely, >12 months) as Braeburn (Brixadi's license holder in the U.S.) received a complete response letter from the FDA. Based on our projections for Sublocade sales growth it is easy to see a near term value for Indivior ordinary shares of 200p." It also states that the Reckitt claim is a " baseless preliminary claim filed by Indivior’s former parent company" that is "procedurally defective and substantively precluded due to Reckitt’s alleged acts of fraud or dishonesty." I agree with the Report and believe that the Reckitt claim was a crude attempt to try & stifle a much stronger claim by INDV on Reckitt. This is also the view taken by the Report. It goes on to forecast an share price of £5 for INDV by 2025 based on INDV's market leading position and on the growth of SUBLOCADE as well as other products supplied by INDV using their monthly injectable technology such as PERSERIS designed to combat Schizophrenia. INDV's share price should continue to firm from here on the run-up to releasing its full year results on 18th February.
15/1/2021
17:52
grupo guitarlumber: Indivior is the biggest FTSE 250 gainer today. Would I buy it now? Manika Premsingh | Friday, 15th January, 2021 Business development to success and FTSE 100 250 350 growth concept. The FTSE 250 opioid addiction treatment provider Indivior (LSE: INDV) is the biggest index gainer today as I write. Its share price is up 9%, continuing its recovery after a sharp fall in late November. Why the share price rose INDV’s better-than-expected financial results are the clear reason for the uptick in share price. It now expects revenue to be at least $25m higher than it had expected earlier for the full year. It also expects expenses to be lower, resulting in an improved income forecast. What’s next for the INDV share price I reckon that the latest news will provide continued impetus for INDV’s share price. It’s now at 115p, up from the sub-100p levels it was at before the last week of December. The big decline started in late November, when it crashed 30% in a day following news that its former parent company — Reckitt Benckiser — had filed a £1bn claim on it. Even now the share price is still much lower than its 131p levels at the time. But at least it’s now closer than ever to getting back there. When I last wrote about Indivior, after its share price fall, my sense was that its share price would be dependent more on its own performance than anything else. If the share price reaction to its latest results is anything to go by, it only proves the point I was making at the time. If its performance remains consistent, I reckon that its share price can climb up further. This is especially so in today’s bullish market, where investors are rewarding companies that are performing well. Battling the opioid crisis Moreover, the seriousness of the opioid crisis is big and rising, an issue that Indivior is well placed to address. According to the World Health Organisation, globally 0.5m deaths are caused by drug use every year, of which 70% are opioid-related. Moreover, between 2010 and 2018, the number of people dying of opioid overdose in the US increased by 120%. Past problems still haunt Despite this, as an investor I’m cautious because of INDV’s problems from the recent past, which include accusations of mis-selling and resulted in its former CEO being imprisoned. Almost two months after I wrote about INDV, it indeed appears to have put the episode behind it. It has also said that Reckitt Benckiser’s claim is without merit. Further, its financials had suffered quite the blow in the first nine months of 2020, with a sharp decline in revenue. The latest numbers, then, are a surprise development and not one that reflects the inherent, ongoing strength of the company. I think the INDV stock looks much better after its results than it did two months ago when it was far more in the thick of a crisis. It could continue to see improvements from here. But I really want to see some more predictability to its financials before buying the stock. Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned.
28/11/2020
09:29
dealy: one thing is for sure: RB didn't file this claim just to tick a box. They would open themselves up to damage claims from Indv investors. There has to be some meaningful compensation goal behind this action
27/11/2020
15:55
waldron: the motely fool Why did the Indivior share price crash 40% on Friday? Alan Oscroft | Friday, 27th November, 2020 | Drug manufacturer Indivior (LSE: INDV) had been soaring in 2020. In fact, as of market close Thursday, the Indivior share price had more than trebled so far this year. But that came to a crunching halt Friday with a whopping 40% crash. Indivior is still ahead more than 100% year-to-date, but what’s happened? Indivior was spun out of Reckitt Benckiser in 2014. And news emerged Friday that its parent has filed a $1bn lawsuit against it. The claim was, apparently, filed on 13 November. It involves an indemnity agreement between the two companies, signed at the time of their parting. 5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit! According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air… And if you click here we’ll show you something that could be key to unlocking 5G’s full potential... In its announcement, Indivior said: “The claim has not been served on the company and the company does not have any further details at this time. The company will assess with its advisors the background and merits to the case and will provide an update in due course.“ More legal pressure for Indivior So we don’t have the details yet. But it’s telling that Indivior has been facing lawsuits related to its opioid dependency treatment Suboxone. The opioid dependency scandal is huge in the US. But it had seemed the matter was resolved after a previous US court case. On 13 November, Indivior told us that “a United States federal court in the Western District of Virginia has approved the agreement between the group and the U.S. Department of Justice and other government agencies that was announced on July 24. The court has also dismissed all charges that were returned by a grand jury in April 2019.” The company added that it “is pleased to put this matter behind it and move forward in a manner that provides certainty to its business.” That certainty has now been shattered. Thought it was all over? As part of the earlier agreement, Indivior had to pay $600m. Prior to that, in October, former CEO Shaun Thaxter had received a six-month jail sentence on charges relating to misrepresentation of the safety of Suboxone. Reckitt Benckiser had had to stump up $1,4bn to try to put it all behind it. And if that wasn’t enough, Indivior has been trying to fight off generic competitors who claim its patent has expired. That’s quite a story for a FTSE 250 company that, by Friday afternoon at least, has still seen its share price double in 2020. But what now? A tense wait Well, we’ll clearly need to wait and find out the details of the Reckitt Benckiser lawsuit. And how nice of Indivior to release the news on a Friday, to give investors time to stew over the weekend with no real hope of further information. Perhaps obviously, I wouldn’t buy now. But I generally wouldn’t invest in a company that’s been facing big legal problems anyway. And definitely not one connected with the US opioid dependency drama.
22/11/2020
13:32
the grumpy old men: RNS Number : 0258G Indivior PLC 20 November 2020 Indivior PLC - Appointment of Chief Financial Officer Slough, UK, and Richmond, VA, November 20, 2020 - The Board of Directors of Indivior PLC are pleased to announce the appointment of Ryan Preblick as Chief Financial Officer and Executive Director with immediate effect. Ryan has been serving as Interim Chief Financial Officer since June 2020 and has been in financial leadership roles since joining Indivior in 2012. Prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Financial Planning and Analysis Commercial Operations. This role included overseeing all key financial management, analysis and reporting elements of the Group's global business. Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial areas of the US business, the Group's largest business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Philip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support. Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond. Comment by Mark Crossley, Chief Executive Officer Ryan has proven to be a highly capable leader of our finance organization and has performed strongly in his role as Interim Chief Financial Officer. The Board and I are delighted to confirm his appointment as Chief Financial Officer and Executive Director. The Company confirms there is no further information to be disclosed pursuant to LR 9.6.13 in connection with Ryan Preblick's appointment. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior . Investor Contact : Jason Thompson, Indivior Vice President, Investor Relations +1 804-402-7123 Jason.Thompson@indivior.com Media Contacts : UK Tulchan Communications +44 207-353-4200 US IndiviorMediaContacts@indivior.com +1 804-594-0836 -ends-
10/11/2020
19:02
waldron: Indivior to Participate in Upcoming Conferences Tue, 10th Nov 2020 07:00 RNS Number : 7452E Indivior PLC 10 November 2020 Indivior Announces Participation in Upcoming Investor Conferences Slough, United Kingdom and Richmond, Virginia - November 10, 2020 - Indivior PLC (LON: INDV) today announced its participation in the following upcoming investor conferences: · November 16th, 8:00 AM US Eastern Time (ET): Stifel Virtual Healthcare Conference (link). · November 17th, 12:00 PM US Eastern Time (ET): Jefferies Virtual Global Healthcare Conference (link). About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. For Further Information Investor Enquiries Jason Thompson VP, Investor Relations Indivior PLC +1 804 402 7123 jason.thompson@indivior.com Media Enquiries Jonathan Sibun Tulchan Communications US Media Inquiries +44 207 353 4200 +1 804 594 0836 Indiviormediacontacts@indivior.com -ends-
16/10/2020
00:38
waldron: 15 October 2020 Indivior to Announce 2020 Year-to-Date and Q3 Results October 29th Slough, UK, and Richmond, VA, 15 October 2020 - Indivior PLC (LON: INDV) today announced that it will release its 2020 year-to-date and third quarter results on Thursday, October 29th at 11:00 London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the Company's website at www.indivior.com . Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 London time (8:00 a.m. U.S. Eastern) on October 29th. Access the Live Results Webcast October 29th The webcast event will be available on the "Investors" section of the Company's website at www.indivior.com . The webcast link is hxxps://edge.media-server.com/mmc/p/py8oqyrx . Participants also may access the results presentation telephonically: US participants +1-646-741-3167; international participants +44 (0) 2071-928338. Please reference confirmation number 6570529. A replay of the presentation will be available at www.indivior.com . About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
16/7/2020
13:12
la forge: RNS Number : 2368T Indivior PLC 16 July 2020 Indivior to Announce First Half and Second Quarter 2020 Results on July 30th and Host Conference Call Presentation Slough, UK, and Richmond, VA, 16 July 2020 - Indivior PLC (LON: INDV) today announced that it will release its first half and second quarter 2020 results on July 30(th) at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com . Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 p.m. London time (7:00 a.m. U.S. Eastern). Access the Live Webcast / Call for the Results on July 30(th) The live webcast event will be available on the "Investors" section of the company's website at www.indivior.com . The webcast link is hxxps://edge.media-server.com/mmc/p/ot3s33ij . Participants also may access the results presentation telephonically: US participants 1-631-510-7495; international participants +44 (0) 2071 928000. Please reference confirmation number 6735858. A replay of the presentation will be available at www.indivior.com . About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior . Contact: Jason Thompson Vice President, Investor Relations Tel: 804-402-7123 or jason.thompson@indivior.com ### This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END NOREAEXKFEXEEFA (END) Dow Jones Newswires July 16, 2020 08:00 ET (12:00 GMT)
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210413 11:18:39